The small list of cardiac imaging AI solutions to earn Medicare reimbursements just got bigger, following CMS’ move to add an OPPS code for AI-based coronary plaque assessments. That represents a major milestone for Cleerly, who filed for this code and leads the plaque AI segment, and it marks another sign of progress for the business of imaging AI.
With CMS’ October 1st OPPS update, Cleerly and other approved plaque AI solutions now qualify for $900 to $1,000 reimbursements when used with Medicare patients scanned in hospital outpatient settings.
- That achievement sets the stage for plaque AI’s next major reimbursement hurdle: gaining coverage from local Medicare Administrative Contractors (MACs) and major commercial payers.
Cleerly and its qualifying plaque AI competitors join a growing list of Medicare-reimbursed imaging AI solutions, headlined by HeartFlow’s FFRCT solution ($930-$950) and Perspectum’s LiverMultiScan MRI software ($850-$1,150), both of which have since expanded their reimbursements across MAC regions and major commercial payers.
- The last few years also brought temporary NTAP reimbursements for Viz.ai (LVO detection / coordination), Caption Health (echo AI guidance), and Optellum (lung cancer risk assessments), plus a growing number of imaging AI CPT III codes that might lead to future reimbursements.
The new reimbursement should also drive advancements within the CCTA plaque AI segment, giving providers more incentive to adopt this technology, and providing emerging plaque AI vendors (e.g. Elucid, Artrya) a clearer path towards commercialization and VC funding.
CMS’ new plaque AI OPPS code marks a major milestone for Cleerly’s commercial and clinical expansion, and a solid step for the plaque AI segment.
The reimbursement also adds momentum for the overall imaging AI industry, which finally seems to be gaining support from CMS. That’s good news for AI vendors, since it’s pretty much proven that reimbursements drive AI adoption and are often necessary to show ROI.